So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
The Chinese biotech is developing a weight-loss drug in a tablet form that could challenge leading products in the booming anti-obesity market Key Takeaways: The AstraZeneca licensing deal in 2023…
InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
PomDoctor completes U.S. listing ahead of looming Nasdaq crackdown
The online medical services provider raised about $20 million after pricing its shares at the bottom of their range – below a Nasdaq-proposed new minimum threshold of $25 million Key…
Obesity drug maker Sciwind targets IPO, with heavyweight backers
Supported by Tencent and Meituan, the biotech aims to launch a targeted GLP-1 drug next year that could challenge established products, but it faces stiff competition Key Takeaways: • Clinical…
A wild ride for TransThera investors: what’s the story?
The firm’s core drug has passed a minor clinical milestone, but the rally really took off when the stock was included in an array of indices tracked by passive funds…
WORK Medical enters strategic partnerships in bid to explore RWA initiatives
The medical products maker hopes to leverage RWA technology to transform and leverage its current product infrastructure and budding AI business Key Takeaways: WORK Medical has formed a new alliance…
Recent Articles
BRIEF: Shandong Gold’s profit surges 91% in first three quarters
1787.HK
600547.SHG
BRIEF: Midea Group posts rising profit and revenue in third quarter
0300.HK
000333.SHE
BRIEF: ZTE profit plunges 87% in third quarter
0763.HK
000063.SHE
